Skip to main content

Advertisement

Open Peer Review Reports for: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
11 Aug 2017 Submitted Original manuscript
21 Sep 2017 Author responded Author comments - Thomas Ettrich
Resubmission - Version 2
21 Sep 2017 Submitted Manuscript version 2
5 Jun 2018 Reviewed Reviewer Report - Jean Luc Van Laethem
26 Jun 2018 Reviewed Reviewer Report - Somnath Mukherjee
18 Aug 2018 Author responded Author comments - Thomas Ettrich
Resubmission - Version 3
18 Aug 2018 Submitted Manuscript version 3
Publishing
4 Dec 2018 Editorially accepted
29 Dec 2018 Article published 10.1186/s12885-018-5183-y

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement